-
公开(公告)号：US20090010841A1
公开(公告)日：2009-01-08
申请号：US11972130
申请日：2008-01-10
Applicant: Bin Liu , James D. Marks
Inventor： Bin Liu , James D. Marks
IPC: C07K16/30 , C07K16/46 , A61K39/395 , A61K51/10 , C12N15/13 , C12N5/10 , G01N33/574 , C12N5/06 , A61P35/00
CPC classification number: C07K16/3069 , A61K2039/505 , C07K2317/622 , C07K2317/73 , C07K2317/77
Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.
Abstract translation: 本发明提供了新型前列腺癌特异性内化人抗体。 抗体本身有用于预防前列腺癌细胞的生长和/或增殖。 抗体还可以配制成嵌合分子以将效应物（例如细胞毒素，成像试剂，药物等）引导至前列腺肿瘤部位。
-
32.发明申请公开(公告)号：US20090010840A1
公开(公告)日：2009-01-08
申请号：US11943367
申请日：2007-11-20
Applicant: Gregory P. Adams , Eva M. Horak , Louis M. Weiner , James D. Marks
Inventor： Gregory P. Adams , Eva M. Horak , Louis M. Weiner , James D. Marks
IPC: A61K51/00 , C07K16/18 , A61K39/395 , A61K49/00 , C12N15/00 , A61P31/00 , G01N33/574 , C12N5/06 , A61K9/127
CPC classification number: A61K39/395 , A61K51/109 , A61K2039/505 , C07K16/2863 , C07K16/32 , C07K2317/31 , C07K2317/622 , G01N2333/71
Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
Abstract translation: 公开了双特异性单链抗体分子，其可用于治疗与EGFR蛋白家族的成员的过表达相关的各种形式的癌症。
-
公开(公告)号：US20080108135A1
公开(公告)日：2008-05-08
申请号：US11809773
申请日：2007-06-01
Applicant: James D. Marks , Marie Alix Poul
Inventor： James D. Marks , Marie Alix Poul
CPC classification number: A61K47/48823 , A61K9/0019 , A61K31/704 , A61K38/00 , A61K47/6809 , A61K47/6843 , A61K47/6851 , A61K47/6855 , A61K47/6865 , A61K47/6913 , C07K16/2863 , C07K16/2881 , C07K16/3053 , C07K16/32 , C07K2317/10 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/77 , C07K2317/92 , C07K2319/02 , C12N15/86 , C12N2795/10043 , C12N2810/859 , Y10S424/812
Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Abstract translation: 本发明提供新的erbB2结合内化抗体。 称为F5和C1的抗体特异性结合c-erbB2抗原，并且在结合时容易内化到带有c-erbB2标记的细胞中。 还提供了包含与一个或多个效应分子相连的F5和/或C1抗体的嵌合分子。
-
34.发明授权High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection 有权用于癌症靶向和检测的高亲和力抗前列腺干细胞抗原（PSCA）抗体公开(公告)号：US08940298B2
公开(公告)日：2015-01-27
申请号：US12676348
申请日：2008-09-04
Applicant: Anna M. Wu , Robert E. Reiter , Eric J. Lepin , James D. Marks , Yu Zhou
Inventor： Anna M. Wu , Robert E. Reiter , Eric J. Lepin , James D. Marks , Yu Zhou
IPC: A61K39/395 , C07K16/30
CPC classification number: C07K16/3069 , A61K39/39558 , A61K51/1096 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , G01N33/574 , G01N33/57434 , G01N33/57492
Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
Abstract translation: 本发明提供结合癌抗原PSCA的新型高亲和力抗体及其片段。 本发明的抗体可用于癌症诊断，预后，治疗，可视化等。 本发明还提供了用于检测，可视化和治疗表达PSCA的各种癌症的方法。
-
公开(公告)号：US08598321B2
公开(公告)日：2013-12-03
申请号：US12528601
申请日：2008-03-21
Applicant: James D. Marks , Isin N. Geren , Jianlong Lou
Inventor： James D. Marks , Isin N. Geren , Jianlong Lou
IPC: A61K38/00 , A61K38/16 , A61K39/385 , A61K39/40 , A61K39/42 , A01N37/18 , C07K16/00 , C12P21/08 , G01N33/00
CPC classification number: C07K16/40 , C07K16/1282 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
-
Patent Agency Ranking
公开(公告)号：US20110218333A1
公开(公告)日：2011-09-08
申请号：US12928792
申请日：2010-12-16
Applicant: James D. Marks , Marie Alix Poul
Inventor： James D. Marks , Marie Alix Poul
IPC: C07H21/04
CPC classification number: A61K47/48823 , A61K9/0019 , A61K31/704 , A61K38/00 , A61K47/6809 , A61K47/6843 , A61K47/6851 , A61K47/6855 , A61K47/6865 , A61K47/6913 , C07K16/2863 , C07K16/2881 , C07K16/3053 , C07K16/32 , C07K2317/10 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/77 , C07K2317/92 , C07K2319/02 , C12N15/86 , C12N2795/10043 , C12N2810/859 , Y10S424/812
Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Abstract translation: 本发明提供新的erbB2结合内化抗体。 称为F5和C1的抗体特异性结合c-erbB2抗原，并且在结合时容易内化到带有c-erbB2标记的细胞中。 还提供了包含与一个或多个效应分子相连的F5和/或C1抗体的嵌合分子。
-
公开(公告)号：US20110200615A1
公开(公告)日：2011-08-18
申请号：US13055436
申请日：2009-07-30
Applicant: James D. Marks , Jianlong Lou , Maria Consuelos Garcia Rodriguez , Isin N. Geren
Inventor： James D. Marks , Jianlong Lou , Maria Consuelos Garcia Rodriguez , Isin N. Geren
CPC classification number: C07K16/1282 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00
Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Abstract translation: 本公开提供了特异性结合并通常中和肉毒杆菌神经毒素（例如BoNT / A，BoNT / B，BoNT / E等）和由那些抗体结合的表位的抗体。 特异性结合本文提供的中和表位的抗体及其衍生物和/或其他抗体可用于中和肉毒杆菌神经毒素，因此也可用于治疗肉毒中毒。
-
38.发明申请公开(公告)号：US20110171235A1
公开(公告)日：2011-07-14
申请号：US12646705
申请日：2009-12-23
Applicant: James D. Marks , Peter Amersdorfer , Isin Geren , Jianlong Lou , Ali Razai , Maria Consuelo Garcia
Inventor： James D. Marks , Peter Amersdorfer , Isin Geren , Jianlong Lou , Ali Razai , Maria Consuelo Garcia
CPC classification number: C07K16/1282 , A61K2039/507 , C07K2317/21 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Abstract translation: 本发明提供了特异性结合并中和A型（BoNT / A）肉毒杆菌神经毒素和由这些抗体结合的表位的抗体。 特异性结合本文提供的中和表位的抗体及其衍生物和/或其他抗体可用于中和肉毒杆菌神经毒素，因此也可用于治疗肉毒中毒。
-
39.发明申请ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF 有权抗EGFR抗体家族抗体，双抗EGFR抗体家族抗体及其使用方法公开(公告)号：US20100196265A1
公开(公告)日：2010-08-05
申请号：US12515522
申请日：2007-11-20
Applicant: Gregory P. Adams , Eva M. Horak , Louis M. Weiner , James D. Marks
Inventor： Gregory P. Adams , Eva M. Horak , Louis M. Weiner , James D. Marks
IPC: A61K51/10 , C07K16/28 , C07K16/46 , A61K39/395 , A61K39/44 , A61K9/127 , A61K51/12 , C07H21/04 , A61P35/00 , C12N15/74 , C12N5/10
CPC classification number: C07K16/2863 , A61K47/6849 , A61K47/6879 , A61K49/0017 , A61K49/0058 , A61K49/16 , A61K51/1027 , A61K2039/505 , C07K16/32 , C07K2317/31 , C07K2317/622 , C07K2317/73 , C07K2317/75 , C07K2317/76 , G01N33/74 , G01N2333/485
Abstract: Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.
Abstract translation: 公开了抗EGFR家族成员抗体和包含一种或多种抗EGFR家族成员抗体的双特异性抗体。 这些抗体可以用于特异性靶向与EGFR蛋白家族的成员的过表达相关的癌症形式。
-
公开(公告)号：US20100009390A1
公开(公告)日：2010-01-14
申请号：US12463123
申请日：2009-05-08
Applicant: JAMES D. MARKS , YU ZHOU
Inventor： JAMES D. MARKS , YU ZHOU
IPC: G01N33/574 , C07K16/30 , C12N5/00
CPC classification number: C07K16/2863 , A61K47/6849 , A61K47/6907 , A61K47/6913 , C07K2317/622 , C07K2317/77 , C07K2317/92 , G01N2333/71
Abstract: This invention provides antibodies that have improved affinity for the epidermal growth factor receptor (EGFR). In addition, this invention provides microparticles and nanoparticles comprising a plurality of EGFR affinity moieties that are effectively internalized by cells expressing an EGFR.
Abstract translation: 本发明提供对表皮生长因子受体（EGFR）具有改善的亲和力的抗体。 此外，本发明提供了包含多个EGFR亲和部分的微粒和纳米颗粒，其被表达EGFR的细胞有效地内化。
-
-
-
-
-
-
-
-
-
Search Results
56
records
(took 0.058 seconds)
